The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and Wegovy, medications costing the massive government health program billions of dollars a year.

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. The negotiations for the 15 additional drugs, which will be handled by the incoming administration, assure major savings for Americans.